This site is intended for healthcare professionals

CHMP recommends Vyepti for the preventive treatment of migraine.

Read time: 1 mins
Published:15th Nov 2021
H. Lundbeck A/S announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion and recommended granting a marketing authorization to Vyepti (eptinezumab) in the European Union (EU) for the preventive treatment of migraine in adults who have at least 4 migraine days per month.

Subject to final approval by the European Commission, Vyepti will be the first and only approved IV treatment for migraine prevention in EU. CHMP based its positive opinion on the efficacy and safety of Vyepti, which has been demonstrated in two phase III clinical trials (PROMISE-1 in episodic migraine and PROMISE-2 in chronic migraine).

The clinical trial program demonstrated a reduction in monthly migraine days over placebo which was observed for both doses of Vyepti as early as day 1 post-infusion, and a sustained effect on patient-relevant outcomes was observed for up to 96 weeks.

The safety of Vyepti was evaluated in approximately 2,000 patients with migraine who received at least one dose of Vyepti. The most common adverse reactions ( greater than 2 percent and at least 2 percent or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity. In PROMISE-1 and PROMISE-2, 1.9 percent of patients treated with Vyepti discontinued treatment due to adverse reactions.

Condition: Migraine/Headache
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.